当前位置:科学网首页 > 小柯机器人 >详情
甲减患者TSH值对长期健康的影响
作者:小柯机器人 发布时间:2019/9/6 10:07:02

英国伯明翰大学Krishnarajah Nirantharakumar团队,进行了甲状腺功能减退患者的促甲状腺激素浓度和长期健康的纵向研究。相关论文于2019年9月3日发表在《英国医学杂志》上。

甲状腺功能减退症(甲减)是一个非常普遍的全球性健康问题,可能会严重影响患者健康。确诊患者需终生使用甲状腺激素治疗(替代治疗)。该研究探讨了甲减患者的促甲状腺激素(TSH)浓度,是否与全因死亡率升高、心血管疾病和骨折风险增加有关。

研究数据来自一个英国基层医疗机构的电子病历数据库“健康改善网络”(THIN),受试者为1995年1月1日至2017年12月31日发生甲减的成年患者。主要观察指标包括缺血性心脏病、心力衰竭、中风/短暂性缺血性发作、房颤、骨折和死亡率。结果以TSH为时变协变量,拟合到扩展Cox比例风险模型。

162369名甲减患者共进行了863072次TSH测量。与参考TSH范围(2-2.5 mIU / L)相比,高TSH浓度(> 10 mIU / L)时缺血性心脏病和心力衰竭的风险增加,风险比分别为1.18和1.42;低TSH浓度时心力衰竭的风险降低,< 0.1 mIU / L的风险比为0.79,0.1-0.4 mIU / L为0.76。TSH浓度最低或最高时死亡率均显著增加,< 0.1 mIU / L风险比为1.18,4-10 mIU / L为1.29,> 10 mIU / L为2.21。高TSH浓度(> 10 mIU / L)时脆性骨折的风险增加,风险比为1.15。

研究表明,甲减患者的TSH浓度在参考值范围内不会影响长期健康,但当TSH浓度超出这个范围,特别是高于参考值上限时,会对健康产生不良影响。

附:英文原文

Title: Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study

Author: Rasiah Thayakaran, Nicola J Adderley, Christopher Sainsbury, Barbara Torlinska, Kristien Boelaert, Dana umilo, Malcolm Price, G Neil Thomas, Konstantinos A Toulis, Krishnarajah Nirantharakumar

Issue&Volume: 3 September 2019

Abstract:

Objective To explore whether thyroid stimulating hormone (TSH) concentration in patients with a diagnosis of hypothyroidism is associated with increased all cause mortality and a higher risk of cardiovascular disease and fractures.

Design Retrospective cohort study.

Setting The Health Improvement Network (THIN), a database of electronic patient records from UK primary care.

Participants Adult patients with incident hypothyroidism from 1 January 1995 to 31 December 2017.

Exposure TSH concentration in patients with hypothyroidism.

Main outcome measures Ischaemic heart disease, heart failure, stroke/transient ischaemic attack, atrial fibrillation, any fractures, fragility fractures, and mortality. Longitudinal TSH measurements from diagnosis to outcomes, study end, or loss to follow-up were collected. An extended Cox proportional hazards model with TSH considered as a time varying covariate was fitted for each outcome.

Results 162 369 patients with hypothyroidism and 863 072 TSH measurements were included in the analysis. Compared with the reference TSH category (2-2.5 mIU/L), risk of ischaemic heart disease and heart failure increased at high TSH concentrations (>10 mIU/L) (hazard ratio 1.18 (95% confidence interval 1.02 to 1.38; P=0.03) and 1.42 (1.21 to 1.67; P<0.001), respectively). A protective effect for heart failure was seen at low TSH concentrations (hazard ratio 0.79 (0.64 to 0.99; P=0.04) for TSH <0.1 mIU/L and 0.76 (0.62 to 0.92; P=0.006) for 0.1-0.4 mIU/L). Increased mortality was observed in both the lowest and highest TSH categories (hazard ratio 1.18 (1.08 to 1.28; P<0.001), 1.29 (1.22 to 1.36; P<0.001), and 2.21 (2.07 to 2.36; P<0.001) for TSH <0.1 mIU/L, 4-10 mIU/L, and >10 mIU/L. An increase in the risk of fragility fractures was observed in patients in the highest TSH category (>10 mIU/L) (hazard ratio 1.15 (1.01 to 1.31; P=0.03)).

Conclusions In patients with a diagnosis of hypothyroidism, no evidence was found to suggest a clinically meaningful difference in the pattern of long term health outcomes (all cause mortality, atrial fibrillation, ischaemic heart disease, heart failure, stroke/transient ischaemic attack, fractures) when TSH concentrations were within recommended normal limits. Evidence was found for adverse health outcomes when TSH concentration is outside this range, particularly above the upper reference value.

DOI: 10.1136/bmj.l4892

Source: https://www.bmj.com/content/366/bmj.l4892

期刊信息

BMJ-British Medical Journal:《英国医学杂志》,创刊于1840年。隶属于BMJ出版集团,最新IF:27.604
官方网址:http://www.bmj.com/
投稿链接:https://mc.manuscriptcentral.com/bmj